Compare AMRC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | EYPT |
|---|---|---|
| Founded | 2000 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2010 | 2005 |
| Metric | AMRC | EYPT |
|---|---|---|
| Price | $32.50 | $17.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $33.22 | $28.75 |
| AVG Volume (30 Days) | 413.8K | ★ 1.5M |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $1,769,928,000.00 | $7,539,000.00 |
| Revenue This Year | $9.83 | N/A |
| Revenue Next Year | $9.62 | N/A |
| P/E Ratio | $66.96 | ★ N/A |
| Revenue Growth | ★ 28.76 | N/A |
| 52 Week Low | $8.49 | $3.91 |
| 52 Week High | $44.93 | $19.11 |
| Indicator | AMRC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 66.49 |
| Support Level | $29.05 | $11.88 |
| Resistance Level | $34.01 | $19.06 |
| Average True Range (ATR) | 2.22 | 1.20 |
| MACD | 0.12 | 0.54 |
| Stochastic Oscillator | 79.71 | 98.22 |
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.